Clinical Trials
79 trialsNCT06217094 2026-02-18
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
Phase 1 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05737615 2025-09-04
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06707896 2025-06-25
TCR1020-CD8 T Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT05296005 2025-02-07
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT06206876 2025-01-17
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT06216561 2024-08-20
Intraperitoneal LSTA1 in CRS-HIPEC
University of California, San Diego
Phase 1 Withdrawn
NCT06337162 2024-08-09
HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT04833959 2024-06-21
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Stanford University
Phase 1 Withdrawn
NCT04054752 2023-11-02
Vaccine Response With NT-I7
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT06017323 2023-10-25
ProglumidePanc
Georgetown University
Phase 1 Withdrawn
NCT05043987 2023-09-07
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
Phase 1 Withdrawn
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04799431 2023-05-09
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Withdrawn
NCT04852367 2023-04-12
PanDox
University of Oxford
Phase 1 Withdrawn
NCT04632199 2022-08-24
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
Ipsen
Phase 1 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT01510561 2021-08-19
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Gilead Sciences
Phase 1 Withdrawn
NCT01273402 2021-08-16
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1 Withdrawn
NCT04270929 2021-06-01
PANC-001
Roger Williams Medical Center
Phase 1 Withdrawn
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT00578396 2021-01-25
Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention
University of California, Irvine
Phase 1 Withdrawn
NCT03760614 2021-01-15
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT04195373 2020-11-25
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
Phase 1 Withdrawn
NCT04270461 2020-10-22
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
Phase 1 Withdrawn
NCT03925428 2020-09-28
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01092689 2020-06-26
The Role of Meat-borne Carcinogens in Pancreatic Cancer
University of Minnesota
Phase 1 Withdrawn
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT04093648 2020-05-20
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Baylor College of Medicine
Phase 1 Withdrawn
NCT03644459 2020-03-11
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Lynkcell Inc.
Phase 1 Withdrawn
NCT03982121 2020-02-17
ISILI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Withdrawn
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT03865563 2020-01-27
Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Withdrawn
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT03738111 2019-09-25
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Lee's Pharmaceutical Limited
Phase 1 Withdrawn
NCT02581501 2019-04-18
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Stamford Hospital
Phase 1 Withdrawn
NCT00968604 2019-04-11
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02868632 2019-04-05
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
Phase 1 Withdrawn
NCT00005030 2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02105350 2018-02-19
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
University Health Network, Toronto
Phase 1 Withdrawn
NCT01956864 2018-02-01
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
Johns Hopkins University
Phase 1 Withdrawn
NCT02106871 2017-10-27
PCC
The University of Texas Medical Branch, Galveston
Phase 1 Withdrawn
NCT02630420 2017-10-26
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Yale University
Phase 1 Withdrawn